Mary-Beth Percival, MD
There is no question that the availability of targeted agents, such as FLT3 inhibitors and IDH1/2 inhibitors, has led to survival gains for patients with acute myeloid leukemia (AML). Despite progress, concerns over the timing and potential toxicities of treatment remain, said Mary-Elizabeth Percival, MD.
“There's still a lot of room to grow. We know that there are a lot of mutations, but finding appropriate inhibitors can be challenging,” said Percival, an assistant professor, Division of Hematology, University of Washington School of Medicine. “Figuring out which inhibitor to use when somebody has multiple mutations is a really challenging area that we haven't crossed the threshold of.”
In an interview during the 2019 OncLive®
State of the Science Summit™ on Hematologic Malignancies, Percival, who is also assistant member in the Clinical Research Division with Fred Hutchinson Cancer Research Center, and an attending physician with the Seattle Cancer Care Alliance, discussed advances and challenges with targeted agents in AML and remaining questions in the field.
... to read the full story